Zheng Quan Ri Bao Wang·2025-07-22 07:10Group 1 - The oral selective histone deacetylase (HDAC) inhibitor Aipusha (Sida Benamine) developed by Shenzhen Micron Biotech Co., Ltd. has been exclusively launched on JD Health, aiming to enhance the accessibility of innovative drugs for patients [1][2] - Aipusha was approved in 2014 for peripheral T-cell lymphoma, filling a gap in treatment options in China, and expanded its indications to solid tumors in 2019, including breast cancer [1] - In 2024, Aipusha received approval for first-line treatment of diffuse large B-cell lymphoma, providing significant and sustainable event-free survival benefits for newly treated patients, with good safety profile [1] Group 2 - Micron Biotech is the first company to pass the review on the Sci-Tech Innovation Board and the first listed biopharmaceutical company in China, positioning itself as a pioneer in the field of original innovative drugs [2] - The exclusive launch of Aipusha on JD Health represents a significant step in deepening cooperation between the two companies, facilitating efficient access to innovative therapies for more patients [2] - JD Health will leverage its full-channel resources and healthcare service ecosystem to provide a one-stop service for patients, including drug consultation, online diagnosis, and precise medication guidance, aiding in the rapid market penetration of Aipusha [2]